Intraocular safety and pharmacokinetics of hexadecyloxypropyl-cidofovir (HDP-CDV) as a long-lasting intravitreal antiviral drug

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 13, 2011, Pages 9391-9396

  Wang, Haiyan ^a,b   Chhablani, Jay ^a   Freeman, William R ^a   Beadle, James R ^c   Hostetler, Karl Y ^c   Hartmann, Kathrin ^a   Conner, Laura ^a   Aldern, Kathy A ^c   Pearson, Lindsey ^a   Cheng, Lingyun ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; PRODRUG; CYTOSINE; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS RETINITIS; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; EYE FUNDUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAOCULAR PRESSURE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RABBIT; SCINTILLATION COUNTING; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; CILIARY BODY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; FOLLOW UP; HYDROLYSIS; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; RETINA; VITREOUS BODY;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CILIARY BODY; CYTOMEGALOVIRUS RETINITIS; CYTOSINE; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HYDROLYSIS; INTRAVITREAL INJECTIONS; PHOSPHONIC ACIDS; RABBITS; RETINA; VITREOUS BODY;

EID: 84863807098     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8293     Document Type: Article

References (24)

1. Jabs DA, Ahuja A, Van Natta M, Lyon A, Srivastava S, Gangaputra S. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes. Ophthalmology. 2010; 117:2152-2161 e2151-2152.
2. Holland GN. AIDS and ophthalmology: the first quarter century. Am J Ophthalmol. 2008;145:397-408.
3. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis. 1991;163:716-719.
4. Weinberg A, Jabs DA, Chou S, et al. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis. 2003;187: 777-784.
5. Cheng L, Hostetler KY, Lee J, et al. Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. Invest Ophthalmol Vis Sci. 2004;45:4138-4144.
6. Cheng L, Hostetler K, Valiaeva N, et al. Intravitreal crystalline drug delivery for intraocular proliferation diseases. Invest Ophthalmol Vis Sci. 2010;51:474-481.
7. Lu S, Cheng L, Hostetler KY, et al. Intraocular properties of hexadecyloxypropyl-cyclic-cidofovir in Guinea pigs. J Ocul Pharmacol Ther. 2005;21:205-209.
8. Cheng L, Beadle JR, Tammewar A, Hostetler KY, Hoh C, Freeman WR. Intraocular pharmacokinetics of a crystalline lipid prodrug, octadecyloxyethyl-cyclic-cidofovir, for cytomegalovirus retinitis. J Ocul Pharmacol Ther. 2011;27:157-162.
9. Cheng L, Hostetler KY, Lee J, et al. Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. Invest Ophthalmol Vis Sci. 2004;45:4138-4144.
10. Randhawa P, Farasati NA, Shapiro R, Hostetler KY. Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob Agents Chemother. 2006;50:1564-1566.
11. Ortiz A, Justo P, Sanz A, et al. Tubular cell apoptosis and cidofovirinduced acute renal failure. Antivir Ther. 2005;10:185-190.
12. Cundy KC, Lynch G, Shaw JP, Hitchcock MJ, Lee WA. Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits. Curr Eye Res. 1996;15:569-576.
13. Wan WB, Beadle JR, Hartline C, et al. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 2005;49:656-662.
14. Beadle JR, Hartline C, Aldern KA, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother. 2002;46: 2381-2386.
15. Aldern KA, Ciesla SL, Winegarden KL, Hostetler KY. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol. 2003;63:678-681.
16. Balzarini J. Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharm World Sci. 1994;16: 113-126.
17. Eisenberg EJ, Lynch GR, Bidgood AM, Krishnamurty K, Cundy KC. Isolation and identification of a metabolite of cidofovir from rat kidney. J Pharm Biomed Anal. 1998;16:1349-1356.
18. Cheruvu NP, Amrite AC, Kompella UB. Effect of eye pigmentation on transscleral drug delivery. Invest Ophthalmol Vis Sci. 2008;49: 333-341.
19. Nan K, Sun S, Li Y, et al. Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection. Br J Ophthalmol. 2010;94:654-658.
20. Howells L, Godfrey M, Sauer MJ. Melanin as an adsorbent for drug residues. Analyst. 1994;119:2691-2693.
21. Leblanc B, Jezequel S, Davies T, Hanton G, Taradach C. Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul Toxicol Pharmacol. 1998;28:124-132.
22. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114: 855-859.
23. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179-2182.
24. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46:726-733.